KT&G's Midterm Plan: Doubling Sales by 2027

Feb.02.2023
KT&G's Midterm Plan: Doubling Sales by 2027
KT&G plans to invest $3.1 billion in e-cigarette and ginseng health products and double sales by 2027.

KT&G has recently launched a midterm business plan.


According to the plan, KT&G will invest a total of 3.9 trillion Korean won (3.1 billion US dollars) by 2027, with a focus on its electronic cigarette business (including overseas operations) and health supplements containing ginseng.


KT&G has plans to increase its sales revenue to over 100 trillion Korean won by 2027, a 73% growth compared to the estimated sales revenue of 59 trillion Korean won in 2022.


Bang Kyung-man, the Executive Vice President of KT&G, announced that the company now sells its heated non-combustible cigarette brands in 31 different countries, with a primary focus on the European market. Since partnering with various companies, the sales of its product, "lil," have quadrupled. The company is also considering releasing sales data related to "lil," which has not yet been disclosed due to a partnership agreement with PMI.


The company also presented its business expansion strategy, aiming to obtain more than half of its sales revenue from overseas operations by 2027. It is reported that in 2022, about 33% of KT&G's sales revenue comes from overseas operations.


According to Bang, KT&G is considering Kazakhstan and Eastern Europe as potential locations for a new factory. In order to raise the necessary funds, KT&G may sell some of its real estate assets and borrow from banks.


References:


KT&G has rejected the idea of spinning off its ginseng unit and instead plans to double its sales by 2027.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts Observation|VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation
2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.
Nov.19 by 2FIRSTS.ai
Belarusian committee discusses e-cigarette regulation, plans to restrict sales and public display
Belarusian committee discusses e-cigarette regulation, plans to restrict sales and public display
The Belarusian Council of the Republic met to discuss better legal regulation of e-cigarette systems, their circulation and use. It noted frequent requests to ban e-cigarettes and stop children/adolescents from picking up the habit, adding that proper laws here are long overdue to boost national healthy development and protect citizens’ rights.
Sep.23 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Product | Compatible with Terea Sticks and Supporting Dual Heating: HiTaste Unveils New Heated Tobacco Device
Product | Compatible with Terea Sticks and Supporting Dual Heating: HiTaste Unveils New Heated Tobacco Device
HiTaste has introduced its new HNB device, the F10, on social media, highlighting its wrap-around heating and dual-heating features. Similar “dual-heating” and “one-stick-two-sessions” designs were widely showcased at InterTabac 2025, signaling that this technical direction is emerging as a new competitive focus among HNB brands.
Nov.17 by 2FIRSTS.ai
Thai police seize over 50,000 illegal e-cigarettes worth more than 10 million baht, main suspect arrested in Bangkok
Thai police seize over 50,000 illegal e-cigarettes worth more than 10 million baht, main suspect arrested in Bangkok
Thai police cracked an illegal e-cigarette smuggling case, seized 50,000 items worth more than 10 million baht (over 310,000 US dollars), arrested several suspects, and cracked down on a cross-border smuggling network.
Sep.23 by 2FIRSTS.ai
Singapore Charges 14 Over Vape Syndicate Under Organised Crime Act
Singapore Charges 14 Over Vape Syndicate Under Organised Crime Act
Singapore police said 13 people were charged on Oct 30 under the Organised Crime Act over an alleged syndicate supplying vapes locally; a 14th suspect is expected to be charged on Oct 31. All 14 had earlier been charged for possessing, or conspiring to possess, vapes for sale and are remanded. Police said the group allegedly imported vapes from Malaysia. OCA carries up to S$100,000 fine or five years’ jail; vape import/sale offences also face stiff penalties.
Oct.31 by 2FIRSTS.ai